Epilepsy: Seizure Focus Localization

Quick Answer

In drug-resistant focal epilepsy being evaluated for surgery, nuclear imaging helps localize the seizure focus. Interictal FDG-PET shows regional hypometabolism at the epileptogenic zone (classically the mesial temporal lobe). Ictal SPECT — a perfusion tracer (Tc-99m-HMPAO or ECD) injected at seizure onset — shows focal hyperperfusion. Subtracting interictal from ictal SPECT and coregistering to MRI (SISCOM/STATISCOM) improves localization. Interictal and ictal imaging point in opposite directions at the same focus.

Definition

Epilepsy is a disorder of recurrent, unprovoked seizures. Focal (localization-related) epilepsy arises from a discrete epileptogenic zone and is the type amenable to surgery. Drug-resistant epilepsy — failure to control seizures despite adequate trials of two appropriate antiseizure medications — triggers a pre-surgical evaluation in which nuclear imaging plays a localizing role.

Synonyms

Localization-related / focal epilepsy; temporal-lobe epilepsy (TLE); mesial temporal lobe epilepsy with hippocampal (mesial temporal) sclerosis; refractory/pharmacoresistant epilepsy; epilepsy-surgery work-up.

Epidemiology

Epilepsy is common; a substantial minority of patients are drug-resistant. Temporal-lobe epilepsy is the most frequent surgically-remediable syndrome, often due to hippocampal sclerosis. Extratemporal (frontal and other) foci are less common and harder to localize.

Etiology

• Mesial temporal (hippocampal) sclerosis — the classic TLE substrate.
• Focal cortical dysplasia and malformations of cortical development (often mTOR-pathway related).
• Low-grade epileptogenic tumors (DNET, ganglioglioma), cavernous/vascular malformations.
• Post-traumatic, post-infectious/encephalitic, autoimmune (limbic encephalitis), and genetic etiologies.

Pathophysiology & the Zones

Pre-surgical evaluation seeks the epileptogenic zone — the region whose removal renders the patient seizure-free — approximated by several converging "zones" (ictal-onset, irritative, functional-deficit). Interictal hypometabolism on FDG (functional-deficit zone) reflects neuronal loss/dysfunction and diaschisis and typically extends beyond the true focus. Ictal hyperperfusion marks the seizure-onset zone at the moment of injection; perfusion then shifts with propagation, which is why injection timing is decisive.

Genetics & Molecular Biology

A range of genetic contributions exist — ion-channel and synaptic genes in some familial/generalized epilepsies, and mTOR-pathway activation in focal cortical dysplasia and tuberous sclerosis (an area of emerging targeted therapy). Genetics does not usually drive the imaging choice but informs the underlying substrate.

Clinical Presentation

Seizure semiology localizes: mesial temporal seizures with auras (epigastric rising, déjà vu), automatisms, and dyscognitive features; frontal seizures brief, nocturnal, hypermotor. A structured video-EEG captures semiology and ictal EEG, the anchor of the evaluation.

The Pre-Surgical Evaluation (Concordance Model)

No single test defines the focus; localization rests on concordance across:

• Video-EEG (scalp; intracranial/stereo-EEG when needed).
• High-resolution MRI (structural lesion — e.g. hippocampal sclerosis, dysplasia).
• Interictal FDG-PET and ictal/interictal SPECT (SISCOM).
• MEG, fMRI (eloquent cortex/language), and the Wada test (memory/language lateralization).

Imaging supports — it does not replace — this multimodal evaluation.

Imaging Findings by Modality

• MRI: structural substrate (hippocampal sclerosis, dysplasia, tumor); the reference anatomic study.
• Interictal FDG-PET: regional hypometabolism at the focus (high yield in TLE, especially MRI-negative or subtle cases).
• Ictal SPECT (± interictal, SISCOM): focal hyperperfusion at onset; subtraction-coregistration localizes subtle foci.
• MEG / fMRI: source localization and eloquent-cortex mapping.

Radiopharmaceutical Uptake Mechanisms

FDG reflects synaptic glucose metabolism (reduced interictally at the dysfunctional focus). HMPAO/ECD are lipophilic perfusion tracers that fix in the brain within seconds in proportion to perfusion at the moment of injection and redistribute negligibly — enabling injection during a seizure with imaging afterward once the patient is stable.

Typical Tracers

Therapy Indications

• Antiseizure medications first-line; drug resistance triggers surgical evaluation.
• Resective surgery (e.g. anterior temporal lobectomy/amygdalohippocampectomy) — high seizure-freedom rates in well-localized TLE.
• Minimally invasive: laser interstitial thermal therapy (LITT).
• Neuromodulation: vagus-nerve stimulation (VNS), responsive neurostimulation (RNS), deep-brain stimulation (DBS); dietary therapy in selected patients.

Differential / Interpretive Challenges

• Propagation vs onset on ictal SPECT (late injection captures propagation, mislocalizing).
• Widespread interictal hypometabolism extending beyond the true focus.
• Bilateral/"temporal-plus" findings complicating lateralization.
• Dual pathology (e.g. hippocampal sclerosis + dysplasia).

Reporting Checklist

• State interictal vs ictal study and, for SPECT, the injection-to-onset latency (quality-determining).
• Describe lateralization/localization and concordance with EEG/MRI.
• For SISCOM, report the subtraction focus coregistered to MRI.
• Note propagation caveats and any bilateral/extratemporal complexity.

Prognosis

Well-localized, concordant temporal-lobe epilepsy has high post-surgical seizure-freedom rates (commonly ~60–70%+), better with a clear MRI substrate and concordant PET/SPECT. Extratemporal and MRI-negative epilepsy has lower success, where PET/SPECT and intracranial EEG add the most value.

Board Pearls

Interictal and ictal imaging point in opposite directions at the same focus: interictal FDG-PET shows hypometabolism; ictal perfusion SPECT shows hyperperfusion. They are complementary, and concordance with EEG/MRI strengthens the surgical decision.

Ictal SPECT lives or dies by injection timing — the perfusion tracer must be injected within seconds of seizure onset (it fixes at that instant); late injection captures post-ictal/propagation patterns rather than the true onset zone, so a tracer must be at the bedside, ready.

SISCOM/STATISCOM (ictal-minus-interictal subtraction coregistered to MRI) localizes subtle foci neither study shows alone. Read cautiously: interictal hypometabolism extends beyond the focus, and bilateral/temporal-plus or dual pathology complicates lateralization — imaging supports, it does not replace, the multimodal pre-surgical evaluation.

Related Pages

• Tracer: FDG; brain perfusion agents (HMPAO/ECD).
• Related CNS: Brain FDG & dementia imaging, brain tumor PET.
• Pitfalls: Pearls, pitfalls & normal variants.

Figure / Diagram Suggestions

• An opposite-directions teaching pair (interictal FDG hypometabolism vs ictal SPECT hyperperfusion of the same focus).
• A SISCOM workflow (ictal − interictal → coregister to MRI).
• An injection-timing timeline (onset → seconds → propagation) showing why latency matters.

Common Pitfalls

• Ensure the FDG study is truly interictal — an unrecognized seizure near injection (peri-ictal) can normalize or even invert the expected focal hypometabolism; concurrent EEG confirms the state.
• Sedatives and antiseizure drugs (benzodiazepines, barbiturates) globally depress cortical FDG, reducing focal contrast.
• On ictal SPECT, crossed cerebellar hyperperfusion and basal-ganglia/thalamic activation are propagation phenomena — not the seizure-onset zone.
• A structural lesion (tumor, prior resection, malformation) causes hypometabolism that is not itself the epileptogenic focus — correlate with MRI and EEG.

Self-Check (Board-Style)